Breast Cancer

Dr Aditya Bardia Forecasts What’s to Come for the ASCENT Trial in Triple-Negative Breast Cancer

October 25th 2020, 12:00pm

Video

Initial preliminary efficacy and safety data are expected sometime next year, stated Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

This Week in Managed Care: October 23, 2020

October 23rd 2020, 1:30pm

Video

This week, the top managed care news included COVID-19 delays in breast cancer surgery; targeted therapies associated with decreased mortality risk for non–small cell lung cancer; an inside look at a patient’s perspective of early-onset Parkinson disease.

COVID-19 Delays in Breast Cancer Surgery Could Mean More Deaths Over Next Decade

October 20th 2020, 9:30pm

Article

A new analysis predicts close to 3000 additional deaths over a 10-year period in patients who faced delays in breast cancer treatment during the pandemic.

Dr Timothy Yap Reiterates the Unmet Medical Need for Molecularly Targeted Agents in Solid Tumors

October 19th 2020, 9:00pm

Video

Early results on rucaparib/sacituzumab govitecan are promising, but further exploration is needed, stated Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.

Ductal Carcinoma in Situ Associated With Higher Breast Cancer Death Risk

October 12th 2020, 9:30pm

Article

Findings suggest that current standard treatment does not eliminate the risk of breast cancer-specific death in the 20 years after DCIS diagnosis.

Dr Aditya Bardia on How Combining Sacituzumab Govitecan, Talazoparib Amplifies Treatment Response

October 12th 2020, 6:00pm

Video

There is a synthetic lethality between sacituzumab govitecan and a PARP inhibitor, noted Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.

Living Life With Metastatic Breast Cancer From a Male Perspective

October 6th 2020, 9:30pm

Podcast

In this episode of Managed Care Cast, we speak with a male patient with breast cancer who was diagnosed with metastatic disease in 2016 about how he lives his life and what he wants people to know about this rare cancer.

Dr Timothy Yap: PARP/TOP1 Inhibitor Toxicities Can Be Managed Through Targeted Delivery

October 5th 2020, 7:00pm

Video

Targeted tumor delivery of irinotecan through sacituzumab govitecan can help to reduce treatment-related toxicities, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.

Mortality Higher Among Women With Interval vs Screening-Detected Breast Cancers

October 1st 2020, 8:39pm

Article

Results from a study on Canadian women who did and did not participate in a population-based breast cancer screening program show that interval breast cancers are more aggressive and deadlier than screening-detected cancers.

Dr Aditya Bardia Discusses the Advantages of Sacituzumab Govitecan for Triple-Negative Breast Cancer

September 28th 2020, 7:45pm

Video

There is a clear need for better therapies to treat triple-negative breast cancer, especially when progression-free survival is around 2%, says Aditya Bardia, MBBS, MPH, breast medical oncologist at Massachusetts General Hospital, Harvard Medical School.